AZD0120 for Rheumatoid Arthritis

(AURORA Trial)

Not yet recruiting at 9 trial locations

Overseen By AstraZeneca Clinical Study Information Center

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: AstraZeneca

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).

Are You a Good Fit for This Trial?

This trial is for adults with certain autoimmune diseases: systemic sclerosis, necrotizing myositis, or rheumatoid arthritis that's hard to treat. Participants must meet specific health criteria not detailed here.

Inclusion Criteria

I can sign and understand the consent form.

Willingness to remain on/start appropriate, highly effective methods of birth control or other acceptable criteria

My body's systems are functioning well enough for treatment.

Exclusion Criteria

I have a history of cancer or am currently being treated for one, but some cancers may be acceptable.

I don't have any brain conditions that could make the trial unsafe for me.

I have a genetic immune system disorder.

What Are the Treatments Tested in This Trial?

Interventions

• AZD0120

Trial Overview

The study tests AZD0120, a new therapy using modified T-cells targeting two proteins often found in these diseases. It's an early-phase trial to see if it's safe and how well participants can tolerate it.

How Is the Trial Designed?

Group I: AZD0120 Regimen 2 Experimental Treatment 1 Intervention

Participants will receive an infusion of AZD0120 Regimen 2.

Group II: AZD0120 Regimen 1 Experimental Treatment 1 Intervention

Participants will receive an infusion of AZD0120 Regimen 1.

Who Is Running the Clinical Trial?

AstraZeneca

Lead Sponsor

Trials

4,491

Recruited

290,540,000+

Sir Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Dr. Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology

Pascal Soriot

AstraZeneca

Chief Executive Officer since 2012

Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris

Cristian Massacesi

AstraZeneca

Chief Medical Officer since 2021

MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology